Advertisement
Demo

Merck, Pfizer combo treatment boosts kidney cancer survival

Feb 12, 2019 , Reuters
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.


Read the full story...


Trending healthcare news keywords at this moment

drug costs world public heart experts hospital data obesity bills doctors hospitals ebola treatment cases measles swine fever alzheimer's brains brain warning labels scientists tip study deadly patients aha news stroke xifaxan state highlights viewpoints care medicaid lawmakers gun control water law digital research pain half states diabetes vaping cancer vaccine throat surgery young junel fe takes mental proposes approves disease air lung kids workers adults blood pressure risk affect legionnaires' outbreak people linked type fda tb graphic meds hadlima